Immunic Achieves Completion of Dual Phase 3 Trials in Relapsing MS

Immunic announced successful enrollment completion for both large-scale Phase 3 ENSURE clinical trials investigating vidofludimus calcium in relapsing multiple sclerosis. This oral therapy, already with positive Phase 2 data in progressive MS, enters a crucial stage toward registration and possible new market entry. The company also closed a $65 million public offering, securing resources to support readout and commercial expansion. Immunic’s platform delivers immunomodulatory effects with a well-tolerated safety profile, which may position it as an alternative to injectable MS medicines.

PDS Biotech Reports Sustained Success in HPV-Driven Head and Neck Cancer

PDS Biotechnology released updated results from the VERSATILE-002 trial at the ASCO Annual Meeting, reinforcing the safety and efficacy of its lead Versamune HPV immunotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma. With a median follow-up of 22 months across 31 sites, data show durable overall survival and manageable toxicity, supporting ongoing enrollment and new international collaborations. The trial’s structure highlights global teamwork and real-world evidence aggregation in oncology.

Funding Rounds and Collaboration Spotlight:

Early June saw strong venture and public fundraising, including Immunic’s oversubscribed round, as well as new VC entries for early-stage biotech launches. Cross-border deals in small molecules, AI-driven drug discovery, and immunotherapies remain vibrant: highlights include Novo Nordisk-Deep Apple Therapeutics (GPCR targeting), Bristol Myers Squibb-BioNTech (mRNA bispecific antibodies), and Regeneron-Hansoh Pharma (GLP-1/GIP receptor agonists).

Industry Analysis: Innovation Paths in Neurology, Oncology, and Drug Platforms

With late-stage advances in neuroimmunology and immunotherapy, June’s biopharma landscape is shaped by deeper focus on chronic disease pathways and the emergence of oral, biologic, and cell-based platforms. Multinational alliances and funding surges signal continuing appetite for transformative technologies.